Caffeic acid phenethyl ester (CAPE) may be a promising adjuvant treatment in gastric cancer

Journal of Clinical Gastroenterology

Volumn 41, Issue 10, 2007, Pages 871-873

  Ribeiro Jr , Ulysses ^a,b   Safatle Ribeiro, Adriana V ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Rua Treze de Maio   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; CAFFEIC ACID PHENETHYL ESTER; CYCLOOXYGENASE 2; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BACTERIAL COLONIZATION; CANCER ADJUVANT THERAPY; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL STIMULATION; CHRONIC GASTRITIS; EDITORIAL; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; OVERALL SURVIVAL; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; STOMACH EPITHELIUM;

ADJUVANTS, PHARMACEUTIC; CAFFEIC ACIDS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; NF-KAPPA B; PHENYLETHYL ALCOHOL; STOMACH NEOPLASMS;

EID: 37349038992     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31806b5938     Document Type: Editorial

References (35)

1. Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev. 1986;8:1-27.
2. Parkin DM, Pisani P, Ferlay J. Statistics are given for global patterns of cancer incidence and mortality for males and females in 23 regions of the world. CA Cancer J Clin. 1999;49:33-64.
3. Ribeiro U Jr, Safatle-Ribeiro AV, Zilberstein B, et al. Does the intraoperative peritoneal lavage cytology add prognostic information in patients with potentially curative gastric resection? J Gastrointest Surg. 2006;10:170-177.
4. Correa P, Fox J, Fontham E, et al. Ruiz Helicobacter pylori and gastric carcinoma. Serum antibody prevalence in populations with contrasting cancer risks. Cancer. 1990;66:2569-2574.
5. Forman D, Sitas F, Newell DG, et al. Geographic association of Helicobacter pylori antibody prevalence and gastric cancer mortality in rural China. Int J Cancer. 1990;46:608-611.
6. Loffeld RJLF, Willems L, Flendrig GA, et al. Helicobacter pylori and gastric carcinoma. Histopathology. 1990;17:537-541.
7. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Eng J Med. 1991;325:1127-1131.
8. Nomura A, Stemmermann GN, Chyou P-H, et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325:1132-1136.
9. Sipponen P. Gastric cancer-a long-term consequence of Helicobacter pylori infection? Scand J Gastroenterol. 1994;29(suppl 201):24-27.
10. Fennerty MB, Emerson JC, Garewal HS, et al. Association between infection with H. pylori and the presence of a gastric cancer precursor lesion, intestinal metaplasia. GI Cancer. 1995;1:39-43.
11. Farinati F, Valiante F, Germana B, et al. Prevalence of Helicobacter pylori infection in patients with precancerous changes and gastric cancer. Eur J Cancer Prev. 1993;2:321-326.
12. Safatle-Ribeiro AV, Ribeiro U Jr, Clarke MR, et al. Relationship between persistence of Helicobacter pylori and dysplasia, intestinal metaplasia, atrophy, inflammation, and cell proliferation following partial gastrectomy. Dig Dis Sci 1999;44:243-252.
13. Wu CY, Wang CJ, Tseng CC, et al. Helicobacter pylori promotes gastric cancer cells invasion through an NF-kB and COX-2-mediated pathway. World J Gastroenterol. 2005;11:3197-3203.
14. Wee A, Teh M, Kang JY. Association of Helicobacter pylori with HLA-DR antigen expression in gastritis. J Clin Pathol. 1992;45:30-33.
15. Crowe SE, Alvarez L, Dytoc M, et al. Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro. Gastroenterology. 1995;108:65-74.
16. Noach LA, Bosma NB, Jansen J, et al. Mucosal tumor necrosis factor-a, interleukin-1, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol. 1994;29:425-429.
17. Isomoto H, Miyazaki M, Mizuta Y, et al. Expression of nuclear factor-kB in Helicobacter pylori-infected gastric mucosa detected with southwestern histochemistry. Scand J Gastroenterol. 2000;35:247-254.
18. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225-260.
19. Sharma SA, Tummuru MKR, Blaser MJ, et al. Activation of IL-8 gene expression by Helicobacter pylori is regulated by transcription factor nuclear factor-kB in gastric epithelial cells. J Immunol. 1998;160:2401-2407.
20. Barnes PJ, Karin M. Nuclear factor-kB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066.
21. Suganuma M, Kuzuhara T, Yamaguchi K, et al. Carcinogenic role of tumor necrosis factor-α inducing protein of Helicobacter pylori in human stomach. J Biochem Mol Biol. 2006;39:1-8.
22. Keates S, Hitti YS, Upton M, et al. Helicobacter pylori infection activates NF-kB in gastric epithelial cells. Gastroenterology. 1997;113:1099-1109.
23. Yang GF, Deng CS, Xiong YY, et al. Expression of nuclear factor-kappa B and target genes in gastric precancerous lesions and adenocarcinoma: Association with Helicobactor pylori cagA (+) infection. World J Gastroenterol. 2004;10:491-496.
24. Brandt S, Terry KT, Roland HR, et al. NF-kB activation and potentiation of proinflammatory responses by the Helicobacter pylori CagA protein. PNAS. 2005;102:9300-9305.
25. Kim JS, Yoo YD. c-Myc exerts a protective function through ornithine decarboxylase against cellular insults. Mol Pharmacol. 2002;62:1400-1408.
26. Hinz M, Krappmann D, Eichten A, et al. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 1999;19:2690-2698.
27. Safatle-Ribeiro AV, Ribeiro U Jr, Sakai P, et al. Integrated p53 histopathologic/genetic analysis of premalignant lesions of the esophagus. Cancer Detect Prev. 2000;24:13-23.
28. Ribeiro U Jr, Safatle-Ribeiro AV. p53 in clinical contexts: yes or not? Arq Gastroenterol. 2006;43:6-7.
29. Abdel-Latif MMM, Windle HJ, El Homasany BS, et al. Caffeic acid phenethyl ester modulates Helicobacter pylori-induced nuclear factor-kappa B and activator protein-1 expression in gastric epithelial cells. Br J Pharmacol. 2005;146:1139-1147.
30. Hishikawa K, Nakaki T, Fujita T. Oral flavonoid supplementation attenuates atherosclerosis development in apolipoprotein E-deficient Mice. Arterioscler Thromb Vasc Biol. 2005;25:442-446.
31. Carrasco-Legleu CE, Marquez-Rosado L, Fattel-Fazenda S, et al. Chemoprotective effect of caffeic acid phenethyl ester on promotion in a medium-term rat hepatocarcinogenesis assay. Int J Cancer. 2004;108:488-492.
32. Watabe M, Hishikawa K, Takayanagi A, et al. Caffeic acid phenethyl ester induces apoptosis by inhibition of NFkB and activation of Fas in human breast cancer MCF-7 cells. J Biol Chem. 2004;279:6017-6026.
33. Michaluart P, Masferrer JL, Carothers AM, et al. Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation. Cancer Res. 1999;59:2347-2352.
34. Lee KW, Chun KS, Lee JS, et al. Inhibition of Cyclooxygenase-2 expression and restoration of gap junction intercellular communication in Hras-transformed rat liver epithelial cells by caffeic acid phenethyl ester. Ann N Y Acad Sci. 2004;1030:501-507.
35. Wu CS, Chen MF, Lee IL, et al. Predictive role of nuclear factor-κB activity in gastric cancer: a promising adjuvant approach with caffeic acid phenethyl ester. J Clin Gastroenterol. 2007;41:894-900.